Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


08.04.2024

2 Blood
1 BMC Cancer
1 Br J Cancer
1 Br J Dermatol
2 Br J Haematol
1 Cancer
1 Discov Oncol
2 Haematologica
2 Leuk Lymphoma
1 Leukemia


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Blood

  1. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    PubMed        

  2. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
    Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
    PubMed         Abstract available


    BMC Cancer

  3. ZHONG Y, Tan GW, Bult J, Veltmaat N, et al
    Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    BMC Cancer. 2024;24:407.
    PubMed         Abstract available


    Br J Cancer

  4. ABRAHAO R, Brunson A, Ruddy KJ, Li Q, et al
    Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.
    Br J Cancer. 2024;130:1166-1175.
    PubMed         Abstract available


    Br J Dermatol

  5. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
    Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
    Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
    PubMed        


    Br J Haematol

  6. ATALLAH-YUNES SA, Habermann TM, Khurana A
    Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
    Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
    PubMed         Abstract available

  7. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
    Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
    PubMed         Abstract available


    Cancer

  8. GIRI S, Harmon C, Landier W, Chen Y, et al
    Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
    PubMed         Abstract available


    Discov Oncol

  9. LIU Y, Li Y, Zhang C, Yang X, et al
    Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.
    Discov Oncol. 2024;15:105.
    PubMed         Abstract available


    Haematologica

  10. BOURLON C, Roddie C, Menne T, Norman J, et al
    Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
    PubMed         Abstract available

  11. IKEDA D, Oura M, Uehara A, Tabata R, et al
    Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
    PubMed         Abstract available


    Leuk Lymphoma

  12. CUI C, Feng C, Rosenthal N, Wade SW, et al
    Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
    Leuk Lymphoma. 2024 Apr 3:1-10. doi: 10.1080/10428194.2024.2331084.
    PubMed         Abstract available

  13. SONG Y, Li J, Zhou K, Ke X, et al
    Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024 Apr 1:1-6. doi: 10.1080/10428194.2024.2310141.
    PubMed         Abstract available


    Leukemia

  14. REISS DJ, Nakayama Y, Weng AP, Stokes ME, et al
    High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02239.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.